Acquired immune-mediated thrombophilia in lymphoproliferative disorders

References

• Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005;92:1349–1351.
   PubMed Web of Science ®Google Scholar
• Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186–194.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995;74:1597–1603.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
   PubMed Web of Science ®Google Scholar
• Pengo V, Tripodi A, Reber G. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–1740.
   PubMed Web of Science ®Google Scholar
• Asherson RA. The catastrophic antiphospholipid (Asherson’s) syndrome. Autoimmun Rev 2006;6:64–67.
   PubMed Web of Science ®Google Scholar
• Brohée D, Delval L, Cauchie P. CD4 lymphocyte deficiency and non-Hodgkin’s lymphoma in the antiphospholipid syndrome. Ann Oncol 1998;9:921.
   PubMed Web of Science ®Google Scholar
• Davidson SJ, Burman JF, Nicholson AG, Jones DW, Dusmet ME. Factor XII auto-antibodies present in a patient with a B-cell lymphoma. Blood Coagul Fibrinolysis 2005;16:365–367.
   PubMed Web of Science ®Google Scholar
• Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008;17:50–55.
   PubMed Web of Science ®Google Scholar
• Liozon E, Loustaud V, Jauberteau MO, et al. Non-simultaneous malignant lymphoma and antiphospholipid syndrome: 4 cases. Rev Med Interne 2001;22:360–370.
   PubMed Web of Science ®Google Scholar
• Keung YK, Cobos E, Meyerrose GE, Roberson GH. Progressive thrombosis after treatment of diffuse large cell non-Hodgkin’s lymphoma and concomitant lupus anticoagulant. Leuk Lymphoma 1996;20:341–345.
   PubMed Web of Science ®Google Scholar
• Mills RC, Zacharski LR, McIntyre OR. Case report: circulating anticoagulant, autoimmune hemolytic anemia and malignant lymphoma. Am J Med Sci 1977;274:75–81.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin’s lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. Leuk Lymphoma 2001;42:221–223.
   PubMed Web of Science ®Google Scholar
• Stefani PM, Pietrogrande F, Sartori R, Girolami A. Immunosuppression due to MACOP-B does not seem to cure the antiphospholipid syndrome. Haematologica 1999;84:751–752.
   PubMed Web of Science ®Google Scholar
• Zuber M, Gherardi R, Defer G, Gaulard P, Divine M, Zafrani ES. Peripheral neuropathy, coagulopathy and nodular regenerative hyperplasia of the liver in a patient with multiple serologic auto-antibody activities and IgM B-cell lymphoma. J Intern Med 1989;226:291–295.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Kanno M, Matsumoto M, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. Neurology 2004;63:1731–1733.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Ancochea J, De Buen C, Merino JL, Marqués G, Vivanco F. Acquired C1-inhibitor deficiency associated with a lupus-like anticoagulant activity. Ann Allergy 1988;61:348–350.
   PubMedGoogle Scholar
• Houbouyan L, Soria J, Soria C, Goguel A. Analysis of an autoimmune antibody (IgM class) in a case of chronic lymphocytic leukaemia. Haemostasis 1974;3:171–182.
   PubMedGoogle Scholar
• Cooper MR, Cohen HJ, Huntley CC, Waite BM, Spees L, Spurr CL. A monoclonal IgM with antibodylike specificity for phospholipids in a patient with lymphoma. Blood 1974;43:493–504.
   PubMed Web of Science ®Google Scholar
• Bellotti V, Gamba G, Merlini G, et al. Study of three patients with monoclonal gammopathies and ‘lupus-like’ anticoagulants. Br J Haematol 1989;73:221–227.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Shichishima T, Yui T, et al. B-cell chronic lymphocytic leukemia is complicated by autoimmune hemolytic anemia and anti-phospholipid syndrome. J Clin Exp Hematopathol 2002;42:75–79.
   Google Scholar
• Vukelja SJ, Krishnan J, Link CM, Salvado AJ, Knight RD. Resolution of pure red cell aplasia and lymphoma: response to intravenous gammaglobulin and combination chemotherapy. Am J Hematol 1989;32:129–133.
   PubMed Web of Science ®Google Scholar
• Miljić P, Milosević-Jovicić N, Antunović P, Bosković D, Basara N, Rolović Z. Recurrent venous thrombosis in a patient with chronic lymphocytic leukemia and acquired protein S deficiency. Haematologia (Budap) 2000;30:51–54.
   PubMedGoogle Scholar
• Ciaudo M, Horellou MH, Audouin J, De Carbonnieres C, Conard J, Samama M. Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: a report of four patients. Am J Hematol 1991;38:271–276.
   PubMed Web of Science ®Google Scholar
• Conley CL, Savarese DM. Biologic false-positive serologic tests for syphilis and other serologic abnormalities in autoimmune hemolytic anemia and thrombocytopenic purpura. Medicine (Baltimore) 1989;68:67–84.
   PubMed Web of Science ®Google Scholar
• Delmer A, Garban F, Le Tourneau A, et al. Waldenström’s macroglobulinemia with prominent splenomegaly and multiple immune disorders. Haematologica 1993;78:408–410.
   PubMed Web of Science ®Google Scholar
• Drusin LM, Litwin SD, Armstrong D, Webster BP. Waldenström’s macroglobulinemia in a patient with a chronic biologic false-positive serologic test for syphilis. Am J Med 1974;56:429–432.
   PubMed Web of Science ®Google Scholar
• Dührsen U, Paar D, Kölbel C, et al. Lupus anticoagulant associated syndrome in benign and malignant systemic disease--analysis of ten observations. Klin Wochenschr 1987;65:852–859.
   PubMedGoogle Scholar
• Gallart T, Benito C, Reverter JC, et al. True anti-anionic phospholipids immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002;116:875–886.
   PubMed Web of Science ®Google Scholar
• Pruzanski W, Warren RE, Goldie JH, Katz A. Malabsorption syndrome with infiltration of the intestinal wall by extracellular monoclonal macroglobulin. Am J Med 1973;54:811–818.
   PubMed Web of Science ®Google Scholar
• Tait RC, Oogarah PK, Houghton JB, Farrand SE, Haeney MR. Waldenström’s macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption. J Clin Pathol 1993;46:678–680.
   PubMed Web of Science ®Google Scholar
• Wisløff F, Michaelsen TE, Godal HC. Monoclonal IgM with lupus anticoagulant activity in a case of Waldenström’s macroglobulinaemia. Eur J Haematol 1987;38:456–460.
   PubMed Web of Science ®Google Scholar
• von Landenberg P, Schölmerich J, Andreesen R, Vogelhuber M, Lackner KJ. A case of Waldenstroem’s disease with a monoclonal IgM antiphospholipid antibody. Rheumatol Int 2002;22:129–131.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Chatterji M, Rahemtullah A. Case records of the Massachusetts General Hospital.Case 39-2008. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008;359:2707–2718.
   PubMed Web of Science ®Google Scholar
• Colović N, Miljić P, Colović M, Milosević-Jovcić N, Multiple M components in two patients with splenic lymphoma with villous lymphocytes. Ann Hematol 2006;85:51–54.
   PubMed Web of Science ®Google Scholar
• Manner H, Jung B, Tonassi L, et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008;335:394–397.
   PubMed Web of Science ®Google Scholar
• McGuire D, Zeidman A, Mittelman M. Non-Hodgkin’s lymphoma presenting with coagulopathy due to anti-phospholipid antibody syndrome. Leuk Lymphoma 1997;26:193–196.
   PubMed Web of Science ®Google Scholar
• McLean-Tooke A, Stroud C, Sampson A, Spickett G. Falsely normal C4 in a case of acquired C1 esterase inhibitor deficiency. J Clin Pathol 2007;60:565–566.
   PubMed Web of Science ®Google Scholar
• Murakami H, Irisawa H, Saitoh T, et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 1997;56:173–178.
   PubMed Web of Science ®Google Scholar
• Sawamura M, Yamaguchi S, Murakami H, et al. Multiple autoantibody production in a patient with splenic lymphoma. Ann Hematol 1994;68:251–254.
   PubMed Web of Science ®Google Scholar
• Sugisaki K, Itoh K, Tamaru J. Acquired C1-esterase inhibitor deficiency and positive lupus anticoagulant accompanied by splenic marginal zone B-cell lymphoma. Clin Exp Rheumatol 2007;25:627–629.
   PubMed Web of Science ®Google Scholar
• Veneri D, Ambrosetti A, Franchini M, Mosna F, Poli G, Pizzolo G. Remission of severe antiphospholipid syndrome associated with non-Hodgkin’s B-cell lymphoma after combined treatment with rituximab and chemotherapy. Haematologica 2005;90(Suppl.):ECR37.
   PubMedGoogle Scholar
• Voinchet H, Etienne G, Ghiringelli CB, et al. Splenic marginal zone lymphoma and autoimmunity: report of six cases. Rev Med Interne 2010;31:4–11.
   PubMed Web of Science ®Google Scholar
• Yokoi T, Mori S, Sugimoto H, et al. Splenic marginal zone lymphoma associated with antiphospholipid antibodies. Rinsho Ketsueki 2004;45:1095–1099.
   PubMedGoogle Scholar
• Arruda VR, Bizzacchi JM, Metze IL. Hairy cell leukemia and multiple autoimmune manifestations in a human immunodeficiency virus-infected patient. Ann Hematol 1993;66:325–327.
   PubMed Web of Science ®Google Scholar
• Duncombe AS, Dalton RG, Savidge GF. Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy. Br J Haematol 1987;65:120–121.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick J, Danks RR, Eikram M. Hairy cell leukemia with an associated lupus-type anticoagulant. J Am Osteopath Assoc 1999;99:109–12, 116.
   PubMedGoogle Scholar
• Richard C, Sedano MC, Mázorra F, et al. Hairy-cell leukaemia associated with auto-immune disorders in the form of a ‘lupus-type’ anticoagulant and a positive direct Coombs’ test. Acta Haematol 1986;75:181–182.
   PubMed Web of Science ®Google Scholar
• Diz-Kucukkaya R, Dincol G, Kamali S, Kural F, Inanc M. Development of hairy cell leukemia in a patient with antiphospholipid syndrome. Lupus 2007;16:286–288.
   PubMed Web of Science ®Google Scholar
• Shinagawa A, Kojima H, Kobayashi T, Kawada K, Nagasawa T. Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells. Int J Hematol 2001;73:526–531.
   PubMed Web of Science ®Google Scholar
• Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K. A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGlambda-type multiple myeloma. Am J Hematol 2004;75:34–39.
   PubMed Web of Science ®Google Scholar
• Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999;62:99–102.
   PubMed Web of Science ®Google Scholar
• Gruber A, Blaskó G Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 1986;42:579–581.
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol 1996;51:319–323.
   PubMed Web of Science ®Google Scholar
• Moore GW, Kamat AV, Gurney DA, et al. Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin’s lymphoma. Clin Lab Haematol 2004;26:429–434.
   PubMedGoogle Scholar
• Carrascosa M, Hernandez JJ, Perez-Castrillon JL, Sampedro I. Antiphospholipid antibodies and Sézary syndrome. Am J Hematol 1995;49:365.
   PubMed Web of Science ®Google Scholar
• Hill VA, Whittaker SJ, Hunt BJ, Liddell K, Spittle MF, Smith NP. Cutaneous necrosis associated with the antiphospholipid syndrome and mycosis fungoides. Br J Dermatol 1994;130:92–96.
   PubMed Web of Science ®Google Scholar
• Onida P, Tresoldi M, Rugarli C. Anti-phospholipid-antibody syndrome associated with peripheral T-cell lymphoma. Am J Hematol 1997;55:167–168.
   PubMed Web of Science ®Google Scholar
• Veysey EC, Wilkinson JD. Mycosis fungoides masquerading as cutaneous lupus erythematosus and associated with antiphospholipid syndrome. Clin Exp Dermatol 2008;33:26–29.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Gonzalez J, Rosenberg R, et al. Cutaneous T-cell lymphoma, tropical spastic paraparesis, cerebral vasculitis, and protein S deficiency in a patient with HTLV-I. South Med J 1996;89:999–1000.
   PubMed Web of Science ®Google Scholar
• Lai S, Walker DH, Elghetany MT. Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury - a case report with pathological and molecular correlative studies. Pathol Int 2005;55:144–149.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Tempescul A, Eveillard JR, Malou M, Berthou C. A possible relationship of lupus anti-coagulant with disease activity in Hodgkin lymphoma. Leuk Lymphoma 2009;50:122–123.
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909–3918.
   Google Scholar
• Chacón JI, , Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648–1654.
   PubMed Web of Science ®Google Scholar
• Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d’Hématologie Cellulaire (GFHC). Br J Haematol 1996;93:731–736.
   PubMed Web of Science ®Google Scholar
• Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström’s macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001;80:722–727.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol 2003;4:679–685.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Oberic L, Buffet M, Schwarzinger M, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist 2009;14:769–779.
   PubMed Web of Science ®Google Scholar
• Carey RW, Harris N. Thrombotic microangiopathy in three patients with cured lymphoma. Cancer 1989;63:1393–1397.
   PubMed Web of Science ®Google Scholar
• Sill H, Höfler G, Kaufmann P, et al. Angiotropic large cell lymphoma presenting as thrombotic microangiopathy (thrombotic thrombocytopenic purpura). Cancer 1995;75:1167–1170.
   PubMed Web of Science ®Google Scholar
• Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009;113:985–994.
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827–1832.
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237–242.
   PubMed Web of Science ®Google Scholar
• Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998;7:15–22.
   PubMed Web of Science ®Google Scholar
• Calvo-Alén J, Toloza SM, Fernández M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.Arthritis Rheum 2005;52:2060–2068.
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–1027.
   PubMed Web of Science ®Google Scholar
• Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35:322–332.
   PubMed Web of Science ®Google Scholar
• Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976;48:499–509.
   PubMed Web of Science ®Google Scholar
• Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica 1997;82:101–105.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006;25:840–844.
   PubMed Web of Science ®Google Scholar
• Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950–1956.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95–103.
   PubMed Web of Science ®Google Scholar
• Genvresse I, Lüftner D, Späth-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002;68:84–90.
   PubMed Web of Science ®Google Scholar
• Pusterla S, Previtali S, Marziali S, et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5:341–346.
   PubMedGoogle Scholar
• Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh 1969;21:482–499.
   PubMedGoogle Scholar
• Thiagarajan P, Shapiro SS, DeMarco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980;66:397–405.
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U. Autoimmune hemolytic anemias, Evans’ syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma 2007;48:1139–1149.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786–92.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115:4991–4998.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530–536.
   PubMed Web of Science ®Google Scholar
• Kasturi J, Saraya AK. Platelet functions in dysproteinaemia. Acta Haematol 1978;59:104–113.
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003;349:1177–1179.
   PubMed Web of Science ®Google Scholar
• Ahn ER, Lander G, Bidot CJ, Jy W, Ahn YS. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005;78:127–129.
   PubMed Web of Science ®Google Scholar
• Tomietto P, Gremese E, Tolusso B, Venturini P, De Vita S, Ferraccioli G. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 2004;92:1150–1153.
   PubMed Web of Science ®Google Scholar
• Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993;81:1801–1807.
   PubMed Web of Science ®Google Scholar